Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis

A subgroup analysis was conducted of patients with carotid atherosclerosis in the NAVIGATE (New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial Versus ASA to Prevent Embolism)-ESUS (Embolic Stroke of Undetermined Source) trial, which was an international, double-blinded, randomized phase 2 trial between December 2014 and September 2017.

Source: Journal of Vascular Surgery - November 22, 2019 Category: Surgery Authors: G. Ntaios, B. Swaminathan, S.D. Berkowitz, R.J. Gagliardi, W. Lang, J.E. Siegler, NAVIGATE ESUS Investigators. Tags: Anticoagulation is not better than aspirin to prevent stroke in patients with carotid atherosclerosis Source Type: research